

Viatriis Appointments Scott A. Smith & Elisha W. Finney to the Company's Board of Directors



Viatriis Inc. a global healthcare company announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatriis' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid.

Scott Smith is a deeply experienced global biotechnology and pharmaceutical executive who currently serves as President and Executive Director of BioAtla, Inc. (NASDAQ: BCAB), a global biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics. Previously, Smith was President and Chief Operating Officer at Celgene Corporation, rising up the ranks from SVP and Global Head of Immunology, and then President of Inflammation and Immunology. Smith is known for his ability to build out, grow and manage large complex organizations. One of his many achievements during his 10-year career at Celgene was overseeing the clinical development, registration, launch and global commercial success of the blockbuster drug Otezla.

In addition to his board membership at BioAtla, Smith is also Chairman of the board of Triumvira Immunologics, Inc. and a member of the Apexigen, Inc. and Refuge Biotechnologies, Inc. boards of directors. He holds a BSc in Chemistry and Biology as well as an HBSc in Pharmacology and Toxicology from the University of Western Ontario and received his MS in International Management from the American Graduate School of International Management.

Elisha Finney is an experienced former public company executive officer and current public company director who most recently served a long and distinguished career at Varian Medical Systems, Inc. as Executive Vice President and Chief Financial Officer, overseeing corporate accounting, corporate communications and investor relations, internal audit, risk management, tax and treasury, and corporate information systems. During her time at Varian, she helped the company grow to be a world-leading manufacturer of medical devices and software for treating cancer and other medical conditions.

Finney currently serves on the boards of directors of Mettler-Toledo International Inc. and NanoString Technologies, Inc., each as Audit Committee Chair, and also serves on the board of directors of ICU Medical, Inc. as Chair of the Nominating and Governance Committee and member of the Audit Committee. She received her B.A. in Risk Management and Insurance from the University of Georgia and her master's degree in Finance from Golden Gate University.

Retiring from the Viatriis board of directors are Neil Dimick and Ian Read. Both have served on the Viatriis board for over two years since the company was created through the combination of Mylan N.V. and Pfizer's Upjohn business in November 2020 (the "Combination").

Robert J. Coury, Executive Chairman of Viatriis said, "On behalf of the entire Viatriis board of directors, we cannot thank Neil and Ian enough for their service and significant contributions over these past years. I have personally and sincerely appreciated their partnership and collaboration as we worked together to lay out a very clear and deliberate two-phased strategy to return Viatriis back to growth. I wish each of them the very best in their future endeavors."

Coury continued, "We are also pleased to welcome Scott Smith and Elisha Finney to the board. Scott's vast commercial and pharmaceutical expertise include not only strong M&A and business development skills, but also sales and marketing, commercial operations and new product development, including regulatory and clinical development strategies. I believe that the Viatriis board will not only benefit from Scott's deep industry knowledge, experience and overall business mindset, but will also be timely as we continue our strategy of moving the company up the pharmaceutical value chain.

"Additionally, Elisha, as a former strong public company senior executive with extensive board credentials, will add value to Viatris' board in the areas of finance, regulatory, reimbursement and risk management. We look forward to working with both Scott and Elisha and the contributions that each will bring to our board."

Neil Dimick said, "It has been my true pleasure to have been able to serve on the Mylan board from 2005 to 2020 and now the Viatris board since the Combination. During this time, I have witnessed firsthand the consistent, significant growth of these companies. I want to personally thank Robert and the entire board of directors for their partnership and strong collaboration. I wish Viatris nothing but the best and am happy to be able to retire knowing that I was able to contribute in paving the way for the company's next phase of growth."

Ian Read stated, "I have sincerely appreciated my time on the Viatris board of directors since the Combination. I believe we have made significant progress during this period not only in establishing an incredibly strong foundation for the company, but in achieving consistent execution against our strategic and financial objectives.

As I conclude my tenure, and as Viatris prepares to enter into phase 2 of its evolution, I am honored to have had the opportunity to contribute to its success."

Source: [Viatris Inc](#)

Published on : Thu, 29 Dec 2022